GSK is cooperating with Save the Children to improve basic healthcare services and access for ethnic minorities in Vietnam.

Driven by 2020’s highlights, international pharma giants are planning to deliver more vital medicines and vaccines to Vietnam in 2021 to tap into local demands and enable the country to weather future crises.

GlaxoSmithKline (GSK) has decided to discontinue HIBERIX in Vietnam due to low medical demand for this vaccine and follow the Pharmaceutical Law.

Multinationals like Sanofi, GSK, Adamed Pharma, and Merck Sharp & Dohme have requested marketing authorisation withdrawal of some pharmaceuticals, with it being unclear if the quality of some popular items is an underlying issue.

The Medical Service Administration, the British Embassy, and the Representative Office of GSK will fight against antimicrobial resistance in 2021-2023.

Burning to take advantage of Vietnam’s new digital transformation in the healthcare sector, international pharma giants like Novartis, AstraZeneca, Sanofi, and GSK are working to align with the new requirements and obtain sustainable gains.

International pharma giants like Pfizer, GSK, and Novartis are expected to be strongly hit soon by a price cut under Vietnam’s new tender rules for branded drugs, enabling local patients to receive an increase in pharmaceutical access at affordable prices.

The EU proposal on the voluntary pooling of patents for coronavirus vaccines, treatments, and tests might be hard to reach, as global pharmaceutical giants stand reluctantly on the sidelines, making a low-cost, globally-available cure a dim prospect.

London-based GSK, the world's sixth-largest pharmaceutical company according to Forbes as of 2019, has taken action to support the global response to COVID-19.

Betting on Vietnam’s future growth potential driven by landmark free trade agreements, investors from both the United States and the ASEAN are releasing new plans to venture further into the lucrative local market, with healthcare being a heavy focus.

Investing in research and development (R&D) and introducing innovative solutions that suit Vietnam’s disease patterns and ensuring that patients have better access to essential medicines and vaccines have been part of GSK’s tireless efforts in Vietnam. Dan Millard, Chief representative of GSK Pte. in Vietnam, talked to VIR’s Hoang Anh about GSK’s 25-year journey of accompanying Vietnamese healthcare professionals in the prevention and treatment of diseases in Vietnam, helping Vietnamese people to do more, feel better, and live longer.

Daniel Millard, chief representative of GSK Vietnam, discussed with VIR’s Bich Thuy about the company’s preparations for the EVFTA.